Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.1% on Insider Buying Activity

Pulse Biosciences, Inc (NASDAQ:PLSE)’s stock price rose 5.1% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $50.09 and last traded at $49.98. Approximately 289,583 shares changed hands during mid-day trading, a decline of 17% from the average daily volume of 347,447 shares. The stock had previously closed at $47.57.

Specifically, COO Liane Rae Teplitsky bought 1,034 shares of Pulse Biosciences stock in a transaction on Friday, August 28th. The stock was acquired at an average cost of $48.35 per share, with a total value of $49,993.90. Following the completion of the acquisition, the chief operating officer owned 2,070 shares in the company, valued at approximately $100,084.50. This represents a 99.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Liane Rae Teplitsky purchased 1,036 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the purchase, the chief operating officer directly owned 1,036 shares in the company, valued at approximately $49,966.28. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Needham & Company LLC started coverage on Pulse Biosciences in a report on Monday, August 17th. They set a “buy” rating and a $58.00 price target for the company. Canaccord Genuity Group upped their price target on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Mizuho set a $45.00 price objective on Pulse Biosciences in a research note on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pulse Biosciences presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Stock Up 5.1%

The stock has a market capitalization of $3.46 billion, a PE ratio of -42.36 and a beta of 1.61. The stock’s 50 day moving average price is $35.38 and its 200-day moving average price is $27.02.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. On average, analysts forecast that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Pulse Biosciences

Several large investors have recently made changes to their positions in PLSE. Osterweis Capital Management Inc. purchased a new position in shares of Pulse Biosciences in the second quarter valued at about $28,000. BNP Paribas Financial Markets raised its stake in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC raised its stake in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. lifted its holdings in Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after purchasing an additional 1,372 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in Pulse Biosciences in the 2nd quarter worth approximately $241,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.